Introduction：Basic information about CAS 1202757-89-8|AVL-292, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | AVL-292 |
|---|
| CAS Number | 1202757-89-8 | Molecular Weight | 423.440 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C22H22FN5O3 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
|---|
| Synonym | More Synonyms |
|---|
AVL-292 BiologicalActivity
| Description | Spebrutinib (AVL-292; CC-292) is a covalent, orally active, and highly selective with an IC50 of 0.5 nM. |
|---|
| Related Catalog | Signaling Pathways >>Protein Tyrosine Kinase/RTK >>BtkResearch Areas >>Cancer |
|---|
| Target | IC50: <0.5 nM (Btk)[1] |
|---|
| In Vitro | Spebrutinib (CC-292) is a covalent, highly selective, orally active inhibitor of Btk with IC50 value of 0.5 nM. Spebrutinib also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC50s of 723 nM, 1.729 μM, 2.43 μM, 4.4 μM, and 7.15 μM, rspectively. Extensive analysis has revealed that the EC50 of Btk occupancy from a Spebrutinib dose-response in Ramos cells (EC50=6 nM) correlated directly with the cellular EC50 of Btk kinase inhibition with Spebrutinib (EC50=8 nM). Furthermore, the concentration at which Spebrutinib inhibits 90% of Btk activity in Ramos cells is 35 nM while the concentration of Spebrutinib required for 90% occupancy of Btk is 39 nM[1]. |
|---|
| Cell Assay | Cells are incubated in serum-free RPMI media for 1-1.5 hours. Isolated human B cells are incubated with Spebrutinib at a final concentration of 0.001, 0.01, 0.1 and 1 μM. Ramos cells are incubated with 0.1 nM-3 μM Spebrutinib. Cells are then incubated in the presence of compound for 1 hour at 37°C. Following incubation, cells are centrifuged and resuspended in 100 μL of serum-free RPMI and BCR is stimulated with addition of 5 μg/mL α-human IgM. Samples are centrifuged, washed in phosphate-buffered saline (PBS), and lysed in 100 μL of Cell Extraction Buffer plus 1:10 (v/v) PhosSTOP Phosphatase Inhibitor and 1:10 (v/v) Complete Protease Inhibitor. Antibodies used for immunoblot analysis include P-PLCγ2, PLCγ2 (3871; CST), Syk (2712; CST), P-Syk (2710; CST), Btk, P-Btk, and Tubulin. Membranes are scanned on a Li-Cor Odyssey scanner using infrared fluorescence detection[1]. |
|---|
| References | [1]. Evans EK, et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Molecular Formula | C22H22FN5O3 |
|---|
| Molecular Weight | 423.440 |
|---|
| Exact Mass | 423.170654 |
|---|
| PSA | 104.12000 |
|---|
| LogP | 2.95 |
|---|
| Index of Refraction | 1.655 |
|---|
Safety Information
Synonyms
| N-{3-[(5-Fluoro-2-{[4-(2-methoxyethoxy)phenyl]amino}-4-pyrimidinyl)amino]phenyl}acrylamide |
| UNII-DRU6NG543J |
| S7173,CC-292 |
| AVL 292 |
| N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide |
| Spebrutinib |
| 2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- |
| AVL-292 |
